# Redlands Community Hospital — Acute Service-Line Market-Entry Analysis & Phased Reclaim-and-Grow Roadmap

### A focused-differentiation service-line plan to recapture leaked community-acuity volume and grow defensibly — so RCH stays independent and is not acquired or forced to sell

**Prepared as a consulting-style engagement | Redlands Health side project | Inland Empire, California | June 2026**

> *Planning analysis built on public/official data (CA HCAI, CMS Care Compare/PDC, IRS Form 990, CMS NPPES, City of Redlands ACFR) and source-of-truth regulatory citations (CA Title 22 CCR, B&P §2400/CPOM, H&S §1340 Knox-Keene, HCAI/OSHPD seismic, AB1415/OHCA, TJC/DNV and ACC/ACS-COT certification standards). Every figure is sourced to a project data file or a named authority. Where a number is modeled rather than sourced it is labeled **(est)**; where the data cannot answer the question it is flagged explicitly. This is a planning document, not legal, actuarial, or clinical advice.*

**Companion file:** `service_line_scorecard.csv` — one row per candidate service line with all eight scoring columns, the weighted score, the tier, and the overall priority rank.

---

## 0. Executive summary

Redlands Community Hospital (RCH) does not have an access problem — it has a **conversion and retention problem at the service-line level.** It wins the front door (≈57–59% home-ZIP ED share on 61,472 visits) but keeps only **36.8% of its core inpatient market** (`rch_market_leakage_analysis.md`), leaking ~63%. The leak splits cleanly into a **structurally-locked** tier (tertiary, Level I trauma, complex pediatrics, quaternary, and Kaiser closed-network volume — roughly two-thirds to ~70% of the core leak per the source CSV) that RCH should **not** chase, and a **community-acuity** tier (~2,500–3,100 recapturable discharges, **est**, after the adversarial re-underwrite in `Strategic_Analysis_Consulting_Report.md`) that the right service lines can win back.

This analysis evaluates **23 candidate service lines** (20 to enter or deepen, plus 3 documented as explicit do-not-enter exclusions) against eight weighted criteria and tiers them into Horizon 1 (0–2 yr), Horizon 2 (2–5 yr), and Horizon 3 (5–10 yr / conditional). The throughline is the directional strategy already adopted: **focused differentiation + forward vertical integration via an RCH-led clinically integrated network (CIN)**, executed at the lowest compliant regulatory rung, with two acute partnerships (**LLUMC Adult** and **Kaiser Fontana/Moreno Valley**) absorbing everything RCH should not build, and alignment with independent specialty groups (on-campus cardiology, Arrowhead Orthopaedics, GI/endoscopy, oncology, OB) feeding the lines RCH does build.

**The H1 sequencing logic in one line:** do the moves that are *cheapest, highest-recapture, and quality-aligned* first — a **Stroke Center** (fixes a live quality liability and stops EMS diversion to LLU), an **ortho/spine + GI + general-surgery ASC** stack (monetizes the existing VRIO franchise and serves daytime workers), an **observation/clinical-decision unit** (converts the ED moat with near-zero capex), and the **prevention/occupational-health/urgent-care access layer** (banks resident and daytime-worker lives into the CIN). The **cardiac cath lab / STEMI center** is the one capital-heavier H1 move justified by its outsized recapture and case-mix lift. Trauma, complex peds, and quaternary care are explicitly excluded and routed to LLU/Arrowhead by partnership.

---

## 1. Method — how each service line was scored

### 1.1 The scoring scale

Every candidate is scored **1–5 on each of eight criteria** (1 = poor / unfavorable, 5 = excellent / favorable). Two criteria are framed so that **higher always means better**, to keep the weighted sum directionally consistent:

- **Capital favorability** — scored *inversely* to capital intensity. 5 = capital-light (e.g., infusion, obs unit); 1 = capital-heavy (e.g., trauma, linac, owned plan). The CSV column is named `Capital_Favorability` and the header states the direction.
- **Time-to-stand-up favorability** — 5 = fast (months); 1 = many years.

The eight criteria, with the weights used to compute the 0–100 weighted score:

| # | Criterion | Weight | What a 5 means |
|---|---|---:|---|
| 1 | **Market need** (IE demographics & disease burden) | 16% | Elevated, sourced IE burden directly drives demand (diabetes 17.0%, HTN 30.2%, obesity 36.5%; aging Pass corridor) |
| 2 | **Leakage-recapture potential** | 18% | Recaptures community-acuity volume now leaking to LLU/Kaiser/ASCs |
| 3 | **Competitive whitespace** | 14% | Genuine gap; no incumbent dominance |
| 4 | **Capital favorability** (lower capital = higher score) | 12% | Capital-light to stand up |
| 5 | **Regulatory / feasibility** (CA Title 22, HCAI, certifications) | 12% | Achievable certification, low licensure friction |
| 6 | **Reimbursement & payer-mix attractiveness** | 10% | Commercial-rich or value-based-monetizable |
| 7 | **Fit with VRIO strengths + prevention-first vision** | 12% | Leverages ED gravity / ortho-spine; advances prevention thesis |
| 8 | **Time-to-stand-up favorability** (faster = higher score) | 6% | Fast to operational |

`Weighted_Score = Σ (criterion_score × weight) × 20`, producing a 0–100 scale. The weights deliberately load **leakage-recapture (18%)** and **market need (16%)** highest, because the explicit mandate is to reclaim the leaked market and grow defensibly; capital and time are real but secondary gates.

### 1.2 Tiering rule

- **H1 (0–2 yr):** weighted score ≥ ~78, *and* capital-favorability ≥ 2, *and* it either fixes a quality liability or directly leverages a VRIO asset. These are the cheapest, highest-recapture, quality-aligned moves.
- **H2 (2–5 yr):** mid-band score (~62–77), or H1-worthy on merit but gated by capital, regulatory lift, or organizational-readiness sequencing (you cannot stand up everything at once — `Strategic_Analysis_Consulting_Report.md` §10.1 caps concurrent net-new initiatives per 18-month window).
- **H3 (5–10 yr / conditional):** depends on the CIN/risk infrastructure maturing first; treated as an earned option, not a commitment.
- **EXCLUDE:** structurally locked (trauma / complex peds / quaternary). Scored to document *why* they are excluded, not to rank them for entry.

### 1.3 The data limitation — stated up front

**The HCAI Patient Origin / Market Share file has no DRG or service-line detail.** It segments encounters only by patient *type* — Inpatient, ED-Only, Ambulatory-Surgery (`rch_market_leakage_analysis.md`, Caveat #2). The record-level Patient Discharge Data (PDD) that *would* carry DRG/MS-DRG, principal diagnosis, and procedure codes is **restricted** (HCAI's confidential, application-gated dataset). Therefore **service-line-level leakage cannot be computed directly from the files in hand.**

This analysis instead reasons from four convergent, sourced evidence streams:

1. **RCH's published service lines and accreditations** (`rch_hospital_data.md` §2.9): ortho/spine US-News High Performing ×4, CoC cancer (2025–27), Maternity Honor Roll, Opioid/SUD Honor Roll — telling us what RCH already does and where it is credible.
2. **Competitor capabilities** (`competitors.md`, `hcai_utilization_comparison.csv`): who holds trauma/peds (LLU, Arrowhead), who runs the freestanding ASCs near campus, where the closed-network walls are (Kaiser).
3. **Inland Empire epidemiology** (`independent_provider_analysis.md` §3): SB County diabetes 17.0%, HTN 30.2%, obesity 36.5% — each above the California average — plus an aging Yucaipa/Calimesa/Pass corridor.
4. **Capacity / utilization** (`hcai_utilization_comparison.csv`): RCH at 56.6% GAC occupancy (real bed headroom) vs. LLUMC 109% and Arrowhead 86% (the two trauma magnets running hot); the surgery mix already tilted outpatient (3,871 outpatient vs. 2,854 inpatient surgeries).

> **Where restricted PDD would sharpen this:** with record-level PDD keyed to RCH's service area, the team could compute *leakage by DRG family* — e.g., exactly how many MS-DRG 280–282 (acute MI) or 061–066 (stroke) cases originate in the core ZIPs and where they go; how much of the LLUMC/Arrowhead pull is genuinely trauma/tertiary (high-MDC-24, ICU, surgical-DRG) vs. community-acuity that RCH *could* keep; and the true commercial-vs-Medi-Cal payer mix of the recapturable pool. That would convert the ~60% tertiary-split *assumption* (`Strategic_Analysis_Consulting_Report.md` §3.4, flagged as an analyst estimate) into a measured number and let the board target specific DRG families rather than service lines in aggregate. Until PDD is obtained, the recapture sizing carries that explicit uncertainty band.

---

## 2. Part A — Service-line inventory and gap analysis

### 2.1 What RCH does today (inventory)

| Layer | RCH current state (sourced) | Strength signal |
|---|---|---|
| **Emergency** | Basic-level ED, 61,472 visits (2024), ~57–59% home-ZIP share, +44% visits since 2018 | **VRIO sustained advantage** — the front door |
| **Orthopedics / spine** | US News High Performing: spinal fusion, hip, knee, pacemaker; Healthgrades America's 100 Best Ortho 2025; hip/knee readmit 0.962 (better than expected) | **VRIO sustained advantage** — the crown jewel |
| **Surgery** | 2,854 inpatient + 3,871 outpatient surgeries (outpatient now the majority of the mix) | Migrating ambulatory — ASC opportunity |
| **Oncology** | ACS Commission on Cancer accredited 2025–2027 | Accredited, defensible to deepen |
| **Women's health / OB** | Maternity Care Honor Roll 2025; perinatal program — but births down 38% (2,161→1,336) | Eroding; defend-or-harvest decision pending |
| **Cardiology** | On-campus independent group (Cardiovascular Specialists of Redlands); **no interventional cath lab / PCI / STEMI-receiving designation found** | **GAP** |
| **Stroke / neuro** | **No Stroke Center certification found; stroke 30-day mortality 18.5 = "Worse than national"** | **GAP + active quality liability** |
| **Behavioral health** | Opioid/SUD Care Honor Roll 2025; two safety-net primary-care clinics; **no owned inpatient psych** | Partial; LLU owns inpatient psych in Redlands |
| **Primary care / prevention** | Two safety-net clinics only; **no owned/aligned PCP base** (CPOM-constrained; Optum/Beaver dominates) | **Biggest value-chain leak (pre-service)** |
| **Post-acute / population health** | Readmissions at/below expected, but **no CIN, no hospital-at-home, no longitudinal management** | **Value-chain leak (after-service)** |

*Sources: `rch_hospital_data.md` §2.9, §4; `rch_quality_scores.csv`; `Strategic_Analysis_Consulting_Report.md` §4 value-chain table.*

### 2.2 The gap versus what leaks to LLU / Kaiser / Arrowhead

The leak decomposes into two buckets. **The line dividing them is the whole strategy.**

**STRUCTURALLY LOCKED — do NOT chase (≈two-thirds to ~70% of the core leak):**

| Locked category | Who holds it | Why RCH cannot/should not win it | Core-market pull |
|---|---|---|---|
| Level I trauma | LLUMC, Arrowhead (the region's only two) | ACS-COT verification + on-call burden is a fixed-cost loser at 211 beds; both magnets run hot (109% / 86%) | embedded in LLU 19.1% + Arrowhead 4.1% |
| Complex / tertiary pediatrics | LLU Children's (364 beds, regional monopoly) | No peds-tertiary capability is attainable at RCH scale | ~9.3% (LLU Children's) |
| Quaternary / academic (transplant, complex CV surgery, complex onc) | LLUMC academic center | No volume/capital/staffing case | embedded in LLUMC pull |
| Kaiser closed-network | Kaiser Fontana/Riverside/Moreno Valley | Kaiser members route to Kaiser regardless of geography | ~10.7% (Fontana) |

*Source: `rch_market_leakage_analysis.md` core-area table; `competitors.md` §3.*

**COMMUNITY-ACUITY — RECAPTURABLE (~2,500–3,100 discharges, est):** This is the residual after removing Kaiser and the genuinely tertiary/trauma/peds share of the LLU+Arrowhead pool. It is the volume RCH *could* keep with the right service-line depth: community cardiac (chest pain, NSTEMI, diagnostic/elective cath), ischemic stroke that does not need thrombectomy, elective ortho/spine and general/GI/uro/ENT surgery now leaking to freestanding ASCs, community oncology/infusion, vascular, and the medical admissions (CHF, pneumonia, COPD, sepsis, cellulitis, diabetic complications) that present in RCH's own ED and then get transferred or chosen-away. **The gap is not geography — these patients are already in RCH's ED — it is service-line depth, on-call specialist coverage, and the credibility to keep them.**

> **Honest flag:** the exact community-acuity tonnage cannot be confirmed without restricted PDD (see §1.3). The ~2,500–3,100 figure is the re-underwritten estimate from `Strategic_Analysis_Consulting_Report.md` Appendix A (which corrected an earlier ~5,108 over-claim down to ~2,500–3,100 after re-running the source CSV); the board case should be anchored at a **40–42% core-share target (+480 to +788 discharges)** and reported in **contribution margin**, not gross revenue, because the recaptured mix is Medi-Cal-skewed.

---

## 3. Part B & C — Candidate evaluation and scoring

The full 23-line scorecard is in `service_line_scorecard.csv`. The table below is the ranked summary (weighted score, tier, binding rationale). Scores are the weighted-formula values in the CSV; **rank follows the weighted score, but the tier is a separate sequencing judgment** — a few lines that score in the high-70s (geriatrics/palliative, hospital-at-home) are placed in H2 because they depend on the CIN/risk rails existing first or fall under the concurrent-initiative cap, while advanced imaging (75) sits in H1 as enabling infrastructure for the H1 acute lines. Where score and tier diverge, the "Why this rank / tier note" column says so.

| Rank | Service line | Score | Tier | Why this rank / tier note |
|---:|---|---:|---|---|
| 1 | **Ortho/spine Center of Excellence + total-joint + ortho ASC** | 91 | H1 | Highest VRIO fit; monetizes the proven franchise; ASC serves daytime + any payer; lowest execution risk |
| 2 | **Primary Stroke Center + neuro** | 86 | H1 | Fixes a live quality liability (stroke mortality "Worse than national") AND stops EMS routing to LLU — quality fix + service line in one |
| 3 | **Urgent care / convenient-access front door** | 86 | H1 | Owns the access front door in RCH's own city; feeds CIN attribution; cheap and fast; fills Optum's 2024 retreat |
| 4 | **Observation medicine / clinical-decision unit** | 85 | H1 | Pure ED-moat conversion; near-zero capex at 56.6% occupancy; the cheapest retention lever |
| 5 | **Occupational health + employer near-/on-site clinics** | 85 | H1 | The daytime-worker monetization line; payer-agnostic B2B; fast, capital-light |
| 6 | **GI / endoscopy + ASC** | 84 | H1 | Margin-positive outpatient; recaptures volume leaking to freestanding ASCs; colorectal screening demand |
| 7 | **Endocrinology / diabetes & cardiometabolic prevention** | 83 | H1 | Bullseye for the prevention vision and IE burden; whitespace; the engine of CIN value-based savings |
| 8 | **General surgery / urology / ENT / bariatrics via ASC** | 81 | H1 | Rides the documented surgery-mix shift to outpatient; bariatrics maps to 36.5% obesity |
| 9 | **Interventional cardiology (cath lab/PCI) + STEMI/Chest-Pain Center** | 78 | H1 | Highest case-mix lift and cardiac recapture; on-campus cardiology de-risks it; the one capital-heavier H1 move worth making (capital drags the score, not the strategic value) |
| 10 | **Geriatrics / palliative** | 77 | H2 | Aging corridor + MA/ACO panels; palliative lowers total cost — but monetized through shared-savings, so it needs the CIN rails first (→ H2) |
| 11 | **Hospital-at-home + SNF-at-home / post-acute** | 77 | H2 | The after-service layer the value chain lacks; targets the high-cost 5% tier; CMS-waiver-dependent and ops-mature (→ H2) |
| 12 | **Wound care + hyperbarics** | 76 | H2 | Maps to diabetes burden (diabetic foot); recurring-visit, favorable reimbursement; vendor-managed lowers risk |
| 13 | **Advanced imaging + interventional radiology** | 75 | H1 | Enabling infrastructure for the H1 stroke/cardiac lines; outpatient imaging serves daytime workers (kept in H1 despite mid-band score) |
| 14 | **Vascular surgery** | 74 | H2 | Synergistic with cardiac/IR/wound/diabetes-PAD; endovascular shifts outpatient |
| 15 | **Pulmonology / sleep** | 74 | H2 | IE air quality + COPD; outpatient sleep is scalable and daytime-friendly |
| 16 | **Pain management** | 73 | H2 | Adjacency to spine COE; interventional pain is ASC-based; opioid-stewardship watch |
| 17 | **Oncology (med/rad/surg onc, infusion, expand CoC)** | 70 | H2 | Builds on accredited CoC; infusion/med-onc capital-light; radiation onc (linac) is JV/defer |
| 18 | **Women's health (defend/grow OB, gyn, urogyn, breast)** | 68 | H2 | Defend-or-harvest OB call required (births −38%); grow gyn/urogyn/breast regardless |
| 19 | **Behavioral health (geri-psych + SUD/MAT + crisis stabilization)** | 66 | H2 | Huge need + SUD honor roll, but LLU owns inpatient psych in Redlands; build outpatient/SUD/crisis, affiliate inpatient |
| 20 | **Nephrology / dialysis** | 66 | H2 | High CKD/ESRD from diabetes/HTN, but DaVita/Fresenius own chronic dialysis; play is inpatient/CKD-in-CIN |
| 97 | **Level I/II Trauma** | 34 | EXCLUDE | Structurally locked — LLU/Arrowhead monopoly; fixed-cost loser; partner/transfer |
| 98 | **Complex pediatrics / peds tertiary** | 34 | EXCLUDE | Structurally locked — LLU Children's monopoly; stabilize-and-transfer only |
| 99 | **Transplant / quaternary** | 27 | EXCLUDE | Structurally locked — LLUMC academic franchise; refer |

### 3.1 Reading the scores — the four logical groupings

- **The quality-and-recapture quartet (H1 core):** Stroke Center, cath lab/STEMI, observation unit, and the ortho/spine COE. Three of the four directly recapture community-acuity *inpatient* leak; the Stroke Center additionally remediates the single worst public quality metric RCH carries. These are the moves that most directly serve the "reclaim the leaked market" mandate.
- **The ambulatory/ASC margin stack (H1):** ortho/spine ASC, GI/endoscopy ASC, general-surgery/uro/ENT/bariatric ASC, advanced imaging. This is where the documented surgery-mix shift (outpatient 3,871 > inpatient 2,854) is monetized at a lower cost basis — and where the **daytime in-commuter workforce** and **any payer's** COE referrals are captured (`commuter_resident_analysis.md` §5c).
- **The prevention/access layer (H1):** endocrinology/cardiometabolic, occupational health, urgent care. Capital-light, whitespace-rich, and the feeder that banks **resident lives** (chronic-disease, longitudinal) and **daytime-worker lives** (episodic, B2B) into the CIN.
- **The H2 depth and after-service build:** wound/HBO, geriatrics/palliative, hospital-at-home, pulmonology/sleep, vascular, pain, oncology deepening, behavioral health, women's-health decision, nephrology. These either need the CIN/risk rails to exist first, carry heavier regulatory/capital lift, or must wait their turn under the concurrent-initiative cap.

---

## 4. Part D — The phased reclaim-and-grow roadmap

Each phase lists the lines to launch/deepen, the certifications and capital required, the partnerships, and — for every line — **how it defends independence** (recaptures leak, adds contribution margin, deepens the moat, feeds the CIN). The resident-vs-daytime segmentation from `commuter_resident_analysis.md` is mapped throughout.

### Phase 0 (concurrent with H1, months 0–6) — the quality gate

Not a service line, but the **stop/go gate** that prices every service-line, payer, and physician conversation (`Strategic_Analysis_Consulting_Report.md` §10.1–10.2):

- **Remediate stroke 30-day mortality** (18.5, "Worse than national") — this is *also* the clinical predicate for the Stroke Center below.
- **Re-enter Leapfrog** (non-participation since Fall 2024 reads as defensiveness to self-funded employers).
- **Reconcile the public 2-star-live vs. 4-star-marketed claim** (a standalone integrity/governance risk).

No physician-group term sheet is signed until Phase 0 is underway. **Capital:** low — clinical-process and governance work, not bricks.

### Phase H1 (0–2 years) — Stop the leak with the cheapest, highest-recapture, quality-aligned moves

| Line | Certifications & capital | Partnership / group | How it defends independence |
|---|---|---|---|
| **Primary Stroke Center + neuro** | TJC or DNV Primary Stroke Center; county EMS stroke-receiving designation. Capital: **low-moderate** (telestroke, protocols, stroke-coordinator FTE, CT already on site). | **LLUMC Adult** as the comprehensive-stroke / thrombectomy backstop for LVO and neuro-IR (RCH does NOT build thrombectomy in H1) | Stops EMS from diverting ischemic-stroke patients to LLU; converts a quality *liability* into a recapture *asset*; resident-lives line |
| **Ortho/spine Center of Excellence + total-joint + ortho ASC** | DNV/TJC ortho-spine COE + total-joint cert; AAAHC/state + CMS ASC accreditation. Capital: **moderate** (ASC build/fit-out; surgeon alignment). | **Arrowhead Orthopaedics** (27+ surgeons, Redlands HQ) via CIN co-management | Monetizes the #1 VRIO franchise; ASC captures elective ortho leaking to freestanding ASCs; serves **daytime in-commuters** and any payer; deepens the moat rivals can't imitate |
| **Interventional cardiology (diagnostic/elective cath) + Chest-Pain Center + STEMI-receiving** | ACC Chest Pain Center accreditation; county EMS STEMI-receiving designation; CDPH cath-lab licensure (Title 22). Capital: **higher** (cath-lab build) — the one capital-heavy H1 exception. | **On-campus Cardiovascular Specialists of Redlands** for staffing; **Kaiser/LLU** for CABG-surgical backup | Recaptures cardiac leak; lifts acuity/case-mix index (better economics per bed-day); on-campus group de-risks; resident-lives line |
| **Observation / clinical-decision unit** | None beyond existing GACH license; CMS observation-billing compliance. Capital: **very low** (protocol + existing beds at 56.6% occupancy). | Internal (built on the ED moat) | Direct ED-moat conversion; retains community-acuity cases that currently transfer out; supports transfer-prevention with zero new tower |
| **GI / endoscopy + ASC** | AAAHC/state + CMS ASC accreditation. Capital: **low-moderate**. | **Inland Gastroenterology + Inland Endoscopy Center**; San Bernardino GI Associates | Recaptures elective endoscopy leaking to nearby ASCs; colorectal-screening volume; commercial-rich outpatient margin |
| **General surgery / urology / ENT / bariatrics via ASC** | AAAHC/state + CMS ASC; MBSAQIP if bariatrics. Capital: **moderate** (shared ASC). | Independent surgical specialists via CIN | Rides the outpatient surgery-mix shift; bariatrics maps to 36.5% obesity; daytime-worker + payer-agnostic COE volume |
| **Endocrinology / diabetes & cardiometabolic prevention** | ADA/AADE DSMES recognition; CDC DPP recognition. Capital: **low**. | CIN PCPs + independent endocrinology; payer VBC contracts | The prevention-first engine; monetized as CIN/shared-savings on the high-cost tier; **resident-lives** anchor |
| **Occupational health + employer near-/on-site clinics** | Clinic licensure; OSHA/occ-med protocols. Capital: **low**. | **Direct-to-employer**: ESRI (self-funded, ~4,890 lives), RUSD, Amazon/Burlington DCs, RCH itself | Captures the ~33,000 **daytime in-commuters**; payer-agnostic B2B revenue + COE referral feeder; banks commercial lives with zero licensure |
| **Urgent care / convenient-access front door** | Clinic licensure only. Capital: **low**. | CIN urgent care (RYMG already owns one); fill Optum's 2024 Redlands/Highland/Beaumont retreat | Owns the access front door before LLU/retail entrench; feeds CIN attribution; routes ED-appropriate volume correctly |

**H1 segmentation map:** the **daytime-worker** lines (ortho/spine ASC, GI/general-surgery ASC, imaging, occupational health, urgent care, COE referrals) are payer-agnostic and sized on the ~39,000-job daytime base; the **resident** lines (Stroke Center, cardiac, observation/medical admissions, endocrinology/cardiometabolic, primary-care-linked prevention) are longitudinal and sized on residence, owning the sticky bedroom-community lives (`commuter_resident_analysis.md` §5c).

### Phase H2 (2–5 years) — Build the system; deepen and add the after-service layer

| Line | Certifications & capital | Partnership / group | How it defends independence |
|---|---|---|---|
| **Advanced imaging + interventional radiology (deepen)** | ACR accreditation (CT/MRI/US/mammo); IR privileging; consider hybrid suite. Capital: **moderate-high**. | Owned/JV vs. RadNet incumbent; on-campus specialists | Enables stroke-thrombectomy pathway, cardiac, onc, vascular; outpatient imaging serves daytime workers |
| **Vascular surgery** | Vascular-lab (IAC) accreditation; hybrid OR for endovascular. Capital: **moderate-high**. | On-campus cardiology/vascular specialists | Recaptures community vascular leaking to LLU; synergy with cardiac/IR/wound + diabetes-PAD burden |
| **Wound care + hyperbarics** | UHMS facility accreditation (optional); HBO chamber safety. Capital: **moderate** (vendor-managed lowers it). | Outpatient wound vendor or owned | Maps to diabetes (diabetic-foot ulcers); recurring-visit favorable reimbursement; feeds vascular/endo |
| **Pulmonology / sleep** | AASM sleep-center accreditation; PFT lab. Capital: **low-moderate**. | Inland Empire Lung & Sleep Institute | IE air quality + COPD; outpatient sleep scalable and daytime-friendly |
| **Pain management** | ASC accreditation; CURES/controlled-substance compliance. Capital: **low**. | Spine surgeons + independent pain specialists | Deepens the spine moat; interventional pain is ASC-based |
| **Oncology (deepen: med onc + infusion; rad-onc via JV)** | Maintain ACS CoC (2025–27); ACR rad-onc if added. Capital: **low** for infusion; **high** for linac (JV/defer). | **Inland Hematology-Oncology Medical Group**; **LLU** for complex/quaternary onc | Recaptures community oncology; infusion is commercial-rich; quaternary stays at LLU |
| **Geriatrics / palliative** | TJC palliative-care cert (optional). Capital: **low** (consult model). | CIN senior panels (Premier Senior); hospice partner | Aging corridor + MA/ACO panels; palliative lowers total cost — monetized in shared-savings |
| **Hospital-at-home + SNF-at-home / post-acute** | CMS Acute Hospital Care at Home waiver (status-dependent); home-health/RPM. Capital: **moderate**. | **Risk-enablement / managed-services partner**; CIN | The after-service layer; targets the high-cost 5% tier (~50% of spend); avoids seismic/bed capex |
| **Behavioral health (SUD/MAT + crisis stabilization + geri-psych; outpatient)** | CDPH psych licensure (Title 22) if inpatient; DHCS/county SUD-MAT; CSU licensure. Capital: **moderate-high**. | **LLU Behavioral Medicine Center** (89 beds, in Redlands) for inpatient transfer/affiliation | Builds on the SUD/Opioid Honor Roll; owns outpatient/crisis where there is whitespace; **affiliates** inpatient rather than competing LLU's tower |
| **Women's health — execute the defend-or-harvest OB decision; grow gyn/urogyn/breast** | NAPBC breast-center accreditation; existing OB/perinatal licensure. Capital: **low-moderate**. | **Inland OB-GYN Associates** | Defend OB as the maternity first-touch feeding **family commercial lives** into the CIN, or right-size it deliberately — but grow gyn/urogyn/breast (outpatient, commercial-rich) either way |
| **Nephrology / CKD-in-CIN (not chronic outpatient dialysis)** | CMS ESRD cert only if owned dialysis (not recommended); CKD management in CIN. Capital: **low** for the CIN play. | **Inland Nephrology Medical Associates**; DaVita JV only if pursued | Inpatient nephrology + CKD prevention in the CIN keeps these patients in-system; concede chronic dialysis chairs to incumbents |

### Phase H3 (5–10 years / conditional) — Own the model

H3 is **not a committed service-line build**; it is the platform that lets the H1/H2 lines capture full margin (`Strategic_Analysis_Consulting_Report.md` §8, §10.1). The relevant "service-line-adjacent" moves:

- **Neuro-interventional / thrombectomy and Comprehensive Stroke Center** — only if volumes, neuro-IR staffing, and the LLU partnership economics justify graduating from Primary to Comprehensive; otherwise keep referring LVO to LLUMC.
- **Radiation oncology (owned linac)** — only if community oncology volume supports the capital; otherwise remain a JV/referral.
- **Provider-sponsored health plan (Restricted → full Knox-Keene)** — the line that lets RCH keep the full premium dollar of the lives its service lines serve. A separate future board capital case; bear global risk only after the CIN demonstrably manages medical cost for multiple years, inheriting RBO solvency from aggregated IPAs.
- **Pass-corridor market development** (Yucaipa → Calimesa → Beaumont/Banning) — outpatient/urgent-care/specialty-access beachheads in the corridor's clearest whitespace (one fragile 79-bed district hospital), feeding the H1/H2 lines upstream.

---

## 5. Part E — Sequencing logic and the explicit "do-not-build" list

### 5.1 Why this order (cheapest, highest-recapture, quality-aligned first)

1. **Stroke Center first because it is two wins in one move.** It remediates the single worst public quality metric RCH carries (stroke mortality 18.5, "Worse than national") *and* it stops EMS from routing ischemic strokes to LLU. It is low-to-moderate capital (the CT scanner already exists; the build is protocols, telestroke, a coordinator, and certification), and it directly attacks recapturable inpatient leak. Nothing else on the list does quality-fix and recapture simultaneously.

2. **Observation unit and the ASC stack next because they are near-free recapture on assets RCH already owns.** The observation/clinical-decision unit converts the ED moat with essentially no capex at 56.6% occupancy. The ortho/spine + GI + general-surgery ASC stack monetizes the documented surgery-mix shift (outpatient already exceeds inpatient) on RCH's strongest franchise, and serves the daytime in-commuter workforce and any payer regardless of where the patient lives.

3. **Cath lab / STEMI center is the one capital-heavier H1 move worth front-loading** because the recapture and case-mix lift are large and the on-campus cardiology group de-risks staffing. It raises acuity/CMI (better economics per bed-day) and recaptures cardiac patients who today leave for LLU. Diagnostic/elective cath first; primary-PCI/STEMI-receiving staged as the program matures; CABG stays a partner referral.

4. **The prevention/access layer runs in parallel** (endocrinology/cardiometabolic, occupational health, urgent care) because it is capital-light, whitespace-rich, and it *feeds the CIN* — banking the resident and daytime-worker lives that the higher-acuity lines then serve. This is the forward-integration spine.

5. **H2 deepening and the after-service layer follow** because they either need the CIN/risk rails to exist first (hospital-at-home, geriatrics/palliative monetized through shared-savings), carry heavier capital/regulatory lift (vascular hybrid suite, behavioral-health licensure, radiation-onc linac), or must wait their turn under the **concurrent-initiative cap** — a money-losing, sub-scale hospital with an incoming CEO cannot stand up everything at once (`Strategic_Analysis_Consulting_Report.md` §10.3, "the fatal risk").

### 5.2 What RCH should NOT attempt — and why partnership is the right answer

| Do NOT build | Why | The partnership answer |
|---|---|---|
| **Level I/II Trauma center** | ACS-COT verification + 24/7 multi-specialty on-call is a fixed-cost loser at 211 beds; LLUMC and Arrowhead already hold the region's only designations and run at 109% / 86% occupancy. Building trauma would buy the lowest-margin, highest-cost volume in the market. | **LLUMC + Arrowhead** absorb trauma; RCH stabilizes and transfers. A clean transfer agreement is worth more than a trauma program. |
| **Complex pediatrics / pediatric tertiary** | LLU Children's (364 beds) is the region's only children's hospital — an unwinnable monopoly. Peds-tertiary subspecialty depth is unattainable at RCH scale. | **LLU Children's** receives peds-tertiary; RCH does basic peds ED stabilization + transfer. |
| **Transplant / quaternary (complex CV surgery, complex onc)** | Quaternary/academic care is LLUMC's franchise; there is no volume, capital, or staffing case for a community hospital. | **LLUMC** is the quaternary referral center; RCH refers and keeps the community-acuity follow-up. |
| **Owning chronic outpatient dialysis chairs** | DaVita/Fresenius dominate; near-zero whitespace and capital-intensive for a commodity service. | Concede the chairs; keep **inpatient nephrology + CKD prevention in the CIN** (where the margin and the prevention story actually are). |

**The strategic point of the partnerships:** the two acute partnerships (**LLUMC Adult** for trauma/peds-tertiary/quaternary/thrombectomy/CABG-backstop; **Kaiser Fontana/Moreno Valley** for what crosses the closed-network line and for capacity overflow) let RCH *concede the unwinnable acuity tiers cleanly* so its capital and management bandwidth go entirely into the recapturable community-acuity lines. Conceding trauma is not weakness — it is the discipline that makes focused differentiation financeable. Every dollar not spent chasing a Level I designation is a dollar that funds the Stroke Center, the cath lab, the ASC, and the CIN that actually keep RCH independent.

### 5.3 How the whole program defends independence

The mandate is to reclaim the area and grow so RCH is **not acquired or forced to sell.** Each tier contributes to that defense:

- **H1 recaptures the leak and adds contribution margin** on assets RCH already owns (the ED, the ortho franchise, 56.6% bed headroom) — flipping the operating line without a balance-sheet-breaking capital program.
- **The ASC and prevention lines deepen the moat** (cost-basis advantage, the convenient front door, the prevention-first differentiation rivals legally cannot match under SB351's hospital carve-out) **and feed the CIN** — aggregating the ~320 independent corridor physicians so referrals default to RCH rather than the LLU magnet, neutralizing Optum's supplier power.
- **H2 builds the after-service layer** (hospital-at-home, palliative, geriatrics) that monetizes the IE's chronic-disease burden through value-based contracts — the only durable margin engine for an independent in a Medi-Cal/Medicare-shifting market.
- **H3 keeps the option to own the full margin** (provider-sponsored plan) earned, not assumed — so RCH grows into a system rather than being absorbed into one.

A hospital that has recaptured its leak, owns its front door, anchors a physician network the giants cannot, and manages the region's chronic disease at risk is **not** a distressed-sale candidate. That is the entire point of the sequence.

---

## 6. Top-line answers

### 6.1 Prioritized H1 service-line shortlist (0–2 years)

Ranked by weighted score (the 10 H1-tier lines; advanced imaging is the 10th, kept in H1 as enabling infrastructure despite a mid-band 75):

1. **Ortho/spine Center of Excellence + total-joint + ortho ASC** (score 91) — monetize the VRIO crown jewel; Arrowhead Orthopaedics.
2. **Primary Stroke Center + neuro** (86) — quality fix + EMS-diversion stop in one; LLUMC backstop.
3. **Urgent care / convenient-access front door** (86) — own the front door; fill Optum's retreat; feeds CIN.
4. **Observation / clinical-decision unit** (85) — near-zero-capex ED-moat conversion; transfer-prevention.
5. **Occupational health + employer near-/on-site clinics** (85) — daytime-worker monetization; direct-to-employer.
6. **GI / endoscopy + ASC** (84) — margin-positive outpatient recapture; Inland GI.
7. **Endocrinology / diabetes & cardiometabolic prevention** (83) — the prevention/CIN engine.
8. **General surgery / urology / ENT / bariatrics via ASC** (81) — ride the outpatient surgery shift.
9. **Interventional cardiology cath lab + Chest-Pain/STEMI center** (78) — the one capital-heavier recapture/case-mix lever (capital drags the score, not its strategic value); on-campus cardiology.
10. **Advanced imaging + interventional radiology** (75) — enabling infrastructure for the stroke and cardiac lines above; outpatient imaging serves daytime workers.

(All gated behind the **Phase 0 quality fix**, and behind the concurrent-initiative cap — sequence *within* H1; do not launch all ten at once. The cardiac cath lab, the one capital-heavy line, is the deliberate front-loaded exception because its recapture and case-mix lift justify the spend.)

### 6.2 Top 3 leakage-recapture opportunities

1. **The ED-to-inpatient retention chain (observation unit + cardiac cath/STEMI + Stroke Center).** RCH already has the patient in its ED at ~57–59% share but admits only ~37% of the area's inpatient cases. Building the service-line depth to *keep* the community-acuity admissions — chest pain/NSTEMI, ischemic stroke, CHF/pneumonia/COPD/sepsis medical admissions — is the single largest recapturable pool, attacked with near-zero new market access.
2. **Elective surgery leaking to freestanding ASCs (ortho/spine + GI + general/uro/ENT).** Three ASCs sit within blocks of RCH's campus capturing elective volume at lower cost; the surgery mix has already tilted outpatient (3,871 > 2,854). An owned/co-owned ASC on the ortho franchise recaptures this margin and serves the daytime in-commuter workforce.
3. **Cardiac volume routing to LLU for want of an interventional program.** With no cath lab/PCI/STEMI-receiving designation, community cardiac cases (the recapturable, non-CABG ones) default to LLU. A cath lab + Chest-Pain Center, staffed by the on-campus cardiology group, recaptures this leak and lifts case-mix.

*(All three are reasoned from RCH's published lines, competitor capabilities, IE epidemiology, and capacity data — not from DRG-level leakage, which requires the restricted HCAI PDD to confirm. See §1.3.)*

### 6.3 Files written

- `service_line_market_entry.md` — this sourced narrative analysis + phased roadmap.
- `service_line_scorecard.csv` — 23 candidate service lines × 8 scored criteria + weighted score + tier + overall priority rank.

---

*Sources referenced: `rch_hospital_data.md`, `rch_market_leakage_analysis.md`, `rch_market_share_leakage.csv`, `rch_patient_origin.csv`, `hcai_utilization_comparison.csv`, `rch_quality_scores.csv`, `competitors.md`, `independent_provider_analysis.md`, `commuter_resident_analysis.md`, `california_regulatory_requirements.md`, `Strategic_Analysis_Consulting_Report.md`. Source-of-truth authorities: CA HCAI (utilization, patient-origin, seismic), CMS Care Compare / Provider Data Catalog (quality), CA Title 22 CCR & H&S §1250 (licensure), B&P §2400 (CPOM), H&S §1340 (Knox-Keene), AB1415/OHCA, TJC/DNV (stroke & cardiac certification), ACC (Chest Pain Center), ACS-COT (trauma), ACS Commission on Cancer, ADA/AADE & CDC (diabetes/DPP recognition).*